Big Losers: Peregrine Pharmaceuticals (NASDAQ:PPHM), VIVUS, Inc. (NASDAQ:VVUS), Chemtura Corporation (NYSE:CHMT)

Lakeway, NY -- (SBWIRE) -- 02/27/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Peregrine Pharmaceuticals (NASDAQ:PPHM) shares dropped 12.95% and closed at $1.21. The company, on Feb. 19, reported data from its randomized, double-blind placebo-controlled Phase II trial of bavituximab in patients with second-line non-small cell lung cancer (NSCLC). Data from the trial has been updated based on completion of an earlier review of discrepancies in the trial and the most current survival data from the trial.

Additionally, Avid Bioservices, Inc., a subsidiary of Peregrine announced that it will present two posters at IBC's Biopharmaceutical Development & Production Conference to be held in Huntington Beach, California, February 26 - March 1, 2013.

Get Latest News, Updates on PPHM Here

VIVUS, Inc. (NASDAQ:VVUS) shares decreased 12.25% to $10.89. The company, on Feb. 25, said its fourth quarter net loss rose to $56.7 million, or 56 cents per share, from $11.5 million, or 13 cents per share, a year earlier. Analysts had expected a loss of 44 cents per share. Fourth-quarter sales of Qsymia were $2 million. Analysts had expected $3.1 million. The company also reported that Qsymia prescriptions jumped about 33 percent to 17,383 from January to February.

Is VVUS a Strong Buying Opportunity After The Recent Slump? Find out Here

Chemtura Corporation (NYSE:CHMT) shares fell 11.84% and closed at $19.36 in the last trading session after CHMT’s stock was downgraded by Oppenheimer from an “outperform” rating to a “market perform” rating in a research note issued yesterday.
Additionally, the company released its earnings data on Monday, February 25th. The company reported $0.27 earnings per share for the quarter, missing the analysts’ consensus estimate of $0.31 by $0.04. The company had revenue of $622.00 million for the quarter, compared to the consensus estimate of $684.00 million.

Is CHMT Signaling a Buy After The Sudden Gain? Don’t Miss Out Free Trend Analysis Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.